Boehringer Ingelheim had committed to adopting Veeva Systems’ Vault CRM, becoming the latest global top 20 biopharma company to make the move.
First announced in 2022 when it was still in the early stages of development, Veeva’s Vault CRM is an enterprise customer relationship management application for biopharma, consumer health, and animal health companies.
Built on the Veeva Vault platform, Vault CRM connects sales, marketing, medical, and service teams with a single customer database supporting the field, including primary care, specialty care, key accounts, retail sales, and medical science liaisons.
Veeva said Vault CRM enables key capabilities such as customer profiling, content sharing and management, territory and account planning, sampling, and recording field engagement.
The Veeva Vault Suite includes nine applications and platforms. Among the most mature are the Vault CRM Approved Email add-on app and the data management platform and customer master application Veeva Network, both first announced in 2013.
Also included is the Vault CRM Events Management app as well as the Vault Align app, both announced in 2015.
Uday Bose, head of human pharma global customer experience excellence and business steering at Boehringer Ingelheim, said Veeva has been their global CRM standard for many years and they are building on that to help shape the future of life sciences through their commitment to move to Veeva Vault CRM.
“We are excited to bring our innovative research to patients around the world with up to 25 new treatment launches by 2030,” he said.
Boehringer Ingelheim is seeking to expand on its existing Veeva Commercial Cloud solutions and its One Medicine and Amplify platforms, which connect development processes and data on Veeva Development Cloud.
“Boehringer Ingelheim has a forward-looking approach to unifying its technology and data landscape to rapidly deliver therapies that improve human and animal health,” said Tom Schwenger, president and chief customer officer at Veeva.
